In summary, we demonstrated that valtrate has antitumor activity in GBM in vitro and in vivo, and the anti-GBM activity is largely due to inhibition of the PDGFRA/MEK/ERK signaling pathway. This evidence concerns the gene MAP2K7 and glioblastoma.